CHWY

Chewy (CHWY) closed the most recent trading day at $21.52, moving 1.74% from the previous trading session.

Over eight quarters, Chewy's revenue climbed steadily while Advance Auto Parts cycled between flat periods and seasonal spikes—a divergence that reveals two very different growth stories.

Chewy (CHWY) jumped onto investor watchlists after its latest results showed revenue above consensus estimates, helping the stock outperform its retail sector peers and raising fresh questions about how durable that momentum might be.

Chewy has seen big swings over the years, and with the stock now around the US$21.93 mark, the live issue is whether that price really matches what its earnings put on the table.

Booking's 20% net margin and $9.1B free cash flow contrast sharply with Chewy's 1.8% margin, but their valuations tell a different story.

Airbnb boasts a 20% net margin and fortress balance sheet, while Chewy's pharmacy expansion offers growth but carries regulatory complexity.

Chewy (CHWY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Chewy (CHWY) concluded the recent trading session at $21.3, signifying a -1.09% move from its prior day's close.

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at online retail stocks, starting with Chewy (NYSE:CHWY).

One dominates through subscription predictability; the other through explosive growth and profitability. Their risk profiles and valuations tell starkly different stories.

Recent reports highlight that Chewy holds an average brokerage recommendation between Strong Buy and Buy. In contrast, a lower Zacks Rank reflects more cautious earnings expectations based on negative estimate revisions.

According to the average brokerage recommendation (ABR), one should invest in Chewy (CHWY). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic.